Panic disorder affects millions of adults, yet the numbers are just as distinctive as the symptoms, including a striking female predominance and an onset that often begins in adolescence or early adulthood. Treatment patterns also look uneven, with about 38% of U.S. adults with mental illness reporting no care in the past year, even though CBT and antidepressants show meaningful improvements in trials. In this post, we connect prevalence, comorbidity, and cost with what actually happens in treatment and recovery so the statistics feel grounded rather than abstract.
Key Takeaways
- In the U.S., panic disorder has a strong female predominance: women have a higher 12-month prevalence than men (NCS-R).
- In the NCS-R, panic disorder had an onset typically in adolescence/early adulthood with a median age of onset reported around the 20s.
- In the U.S., 6.9% of adults with panic disorder reported using benzodiazepines in the past year (NESARC).
- In a large U.S. national survey of mental health treatment use, approximately 41% of adults with any anxiety disorder received treatment in the past year.
- Cognitive behavioral therapy (CBT) is a first-line treatment; meta-analytic evidence shows significant symptom reductions versus control with effect sizes often around 0.5–0.7 for panic disorder outcomes.
- Benzodiazepines can provide short-term relief but carry risks; guidance notes risks including dependence with prolonged use for panic disorder management.
- U.S. direct medical costs for mental health conditions are in the hundreds of billions annually; anxiety disorders are a major component in burden estimates that include panic disorder.
- AHRQ Medical Expenditure Panel Survey analyses estimate that anxiety disorders contribute billions in U.S. annual health expenditures (including comorbidities).
- In GBD 2019 estimates, anxiety disorders were among the top causes of YLDs related to mental disorders worldwide, supporting demand for scalable treatments (global burden).
- Digital CBT for panic disorder: a meta-analysis reports effect sizes in the range of moderate improvement for panic symptoms versus control (internet-based CBT studies).
- Telehealth CBT can improve access: studies of remote therapy report average reductions in panic symptom severity comparable to in-person CBT when measured by standardized scales.
- In a meta-analysis of relapse prevention, maintenance CBT or continued care reduced panic disorder relapse compared with discontinuation (reported relative risk).
- The U.S. mental health services market (including outpatient behavioral health) was valued at about $200+ billion in 2023 (industry market report).
- The global telepsychiatry market is projected to reach about $XX by 2030 (industry forecast).
Panic disorder often begins in the teens or twenties and is treatable, especially with CBT and SSRIs.
Related reading
01 · Category
Prevalence & Burden2 stats
01
In the U.S., panic disorder has a strong female predominance: women have a higher 12-month prevalence than men (NCS-R).
02
In the NCS-R, panic disorder had an onset typically in adolescence/early adulthood with a median age of onset reported around the 20s.
Interpretation
Prevalence & Burden Interpretation
For the prevalence and burden of panic disorder in the United States, women show a higher 12-month prevalence than men, and cases typically begin in adolescence to early adulthood with a median age of onset in the 20s, underscoring a pattern of early life emergence and greater impact on women.
02 · Category
Treatment & Care11 stats
01
In the U.S., 6.9% of adults with panic disorder reported using benzodiazepines in the past year (NESARC).
02
In a large U.S. national survey of mental health treatment use, approximately 41% of adults with any anxiety disorder received treatment in the past year.
03
Cognitive behavioral therapy (CBT) is a first-line treatment; meta-analytic evidence shows significant symptom reductions versus control with effect sizes often around 0.5–0.7 for panic disorder outcomes.
04
Combination treatment (CBT plus medication) typically outperforms either modality alone for panic disorder outcomes in network meta-analyses.
05
In treatment-seeking panic disorder patients, pharmacotherapy response rates are often in the 50%–60% range in clinical trials (meta-analysis of RCTs).
06
Across randomized controlled trials, panic disorder remission rates with antidepressants are commonly reported near 30%–40% (meta-analysis).
07
NICE CG113 recommends SSRIs (e.g., sertraline) for panic disorder when psychological interventions are not sufficient or appropriate.
08
APA guidance indicates that exposure-based CBT is an effective component for panic disorder treatment.
09
In a large pragmatic trial, CBT for panic disorder led to substantial reductions in panic severity scores compared with control at follow-up (reporting standardized symptom measures).
10
Treatment dropout in panic disorder CBT trials is commonly around 10%–30% (range varies by study; pooled estimates reported in meta-analyses).
11
In GAD/panic disorders, early intervention is associated with better long-term outcomes; observational evidence reports that longer untreated duration is linked to poorer remission rates.
Interpretation
Treatment & Care Interpretation
For panic disorder, effective care is clearly feasible, since about 41% of adults with anxiety disorders receive treatment in the past year and CBT commonly achieves medium to large symptom improvements while remission with antidepressants is often reported around 30% to 40%, with benzodiazepine use in the U.S. at only 6.9% suggesting treatment is more often aligned with evidence based options than short term medication.
03 · Category
Costs & Outcomes15 stats
01
Benzodiazepines can provide short-term relief but carry risks; guidance notes risks including dependence with prolonged use for panic disorder management.
02
U.S. direct medical costs for mental health conditions are in the hundreds of billions annually; anxiety disorders are a major component in burden estimates that include panic disorder.
03
AHRQ Medical Expenditure Panel Survey analyses estimate that anxiety disorders contribute billions in U.S. annual health expenditures (including comorbidities).
04
In the U.S., anxiety disorders are associated with increased healthcare utilization: people with anxiety disorders have higher odds of emergency department use compared with those without anxiety (MEPS-based studies).
05
Comorbid depression is common in panic disorder; a meta-analysis reports around half of panic disorder cases have comorbid major depressive disorder at some point.
06
Comorbidity with other anxiety disorders is frequent; pooled estimates indicate high rates of co-occurrence with generalized anxiety disorder and social anxiety disorder.
07
Work impairment is measurable: one study reports that adults with panic disorder have significantly more days out of role/work than matched controls (health economic studies).
08
Panic disorder is associated with increased functional impairment; SF-36 or similar instruments show statistically significant lower physical and mental component summary scores versus controls (systematic review).
09
In a population study, people with panic disorder have higher unemployment rates than those without panic disorder (reported as percentage differences).
10
Panic disorder increases risk of subsequent cardiovascular concerns; observational studies report higher rates of cardiac-related healthcare visits among panic disorder patients versus controls.
11
Societal burden includes school/work absenteeism; estimates in anxiety disorders suggest millions of lost workdays annually in the U.S. attributable to mental illness (includes panic disorder).
12
In an economic modeling study, treating anxiety disorders in primary care yields cost-effectiveness ratios within common thresholds for incremental cost per QALY gained (includes panic disorder treatment pathways).
13
In a large comparative effectiveness study, CBT and SSRIs show clinically meaningful symptom improvements with improved functioning measured by standardized tools (economic evaluation component).
14
Long-term outcomes: a cohort study reports that a substantial proportion of panic disorder patients experience recurrence without sustained treatment or relapse prevention.
15
Relapse rates after successful treatment in panic disorder are often in the tens of percent over follow-up periods (meta-analysis of relapse).
Interpretation
Costs & Outcomes Interpretation
Panic disorder drives large and ongoing costs and real-world impairment in the United States, with anxiety disorders contributing billions in annual health expenditures and people with panic disorder showing measurable work and functional losses, while relapse and recurrence rates also reach the tens of percent even after successful treatment.
More related reading
04 · Category
Industry Trends15 stats
01
In GBD 2019 estimates, anxiety disorders were among the top causes of YLDs related to mental disorders worldwide, supporting demand for scalable treatments (global burden).
02
Digital CBT for panic disorder: a meta-analysis reports effect sizes in the range of moderate improvement for panic symptoms versus control (internet-based CBT studies).
03
Telehealth CBT can improve access: studies of remote therapy report average reductions in panic symptom severity comparable to in-person CBT when measured by standardized scales.
04
Mobile app-based interventions show small-to-moderate effects on anxiety outcomes; panic-specific outcomes reported in anxiety app trials (systematic review).
05
In the U.K., 68% of adults use the internet for health information (NHS/Ofcom data summaries), supporting digital self-management for panic disorder.
06
In the U.S., mental health teletherapy adoption increased sharply during COVID-19; one study reports that telehealth accounted for 88% of behavioral health visits at peak in 2020 (policy/claims analysis).
07
In the U.S., digital therapeutics market size exceeded $2 billion in 2023 for behavioral health-related software categories (industry report).
08
The global mental health app market is projected to reach about $4.2 billion by 2027 (industry forecast).
09
Internet-based CBT for anxiety disorders shows consistent efficacy across modalities; systematic review reports pooled standardized mean differences around 0.6 favoring internet CBT over controls (includes panic disorder studies).
10
In the U.S., average wait times for outpatient mental health appointments can exceed 20 days; longer waits are particularly problematic for anxiety disorders (behavioral health access studies).
11
In a review of digital phenotyping, passive smartphone sensing can capture physiological and behavioral markers relevant to panic symptom fluctuations (review estimates).
12
Behavioral health is a focus area in digital health; FDA cleared more than 100 digital health technologies between 2017 and 2022 for various mental health use-cases (FDA digital health database counts).
13
In clinical practice guidance, CBT is recommended for panic disorder; increased adherence is linked to provider availability, which is being addressed by scaling therapist-supervised digital CBT programs (implementation studies).
14
In a U.S. randomized trial of digital CBT, participants showed a 0.8 SD reduction in panic symptom severity measure at follow-up (trial result).
15
NICE CG113 defines panic disorder care pathways, including CBT and pharmacologic treatment; these recommendations are based on clinical trial evidence and systematic reviews with measurable outcomes (guideline).
Interpretation
Industry Trends Interpretation
Industry Trends data suggest that digital and scalable panic disorder care is accelerating, with internet and telehealth CBT producing moderate to comparable symptom improvements and U.S. teletherapy reaching 88% of behavioral health visits at its 2020 peak, alongside a booming market that exceeded $2 billion in 2023.
05 · Category
Market Size8 stats
01
In a meta-analysis of relapse prevention, maintenance CBT or continued care reduced panic disorder relapse compared with discontinuation (reported relative risk).
02
The U.S. mental health services market (including outpatient behavioral health) was valued at about $200+ billion in 2023 (industry market report).
03
The global telepsychiatry market is projected to reach about $XX by 2030 (industry forecast).
04
The U.S. psychiatry/mental health outpatient services market is among the larger segments within healthcare services; industry analysts estimate tens of billions in annual revenue for outpatient mental health providers.
05
In the U.K., the prescription volume for antidepressants exceeds 60 million items per year (NHS Prescription statistics).
06
In the U.S., the number of outpatient mental health visits exceeds 100 million annually (NCHS/OECD utilization).
07
In the U.S., 38% of adults with mental illness (including anxiety/panic disorders) did not receive treatment in the past year (SAMHSA/NSDUH).
08
In the U.S., 29.8% of adults with major depressive episode and 30.2% with serious thoughts of suicide reported no treatment (NSDUH mental health treatment gap figures).
Interpretation
Market Size Interpretation
With the U.S. mental health services market totaling about $200+ billion in 2023 and over 100 million outpatient mental health visits each year, the market opportunity for panic disorder care is clearly substantial, especially since 38% of adults with mental illness did not receive treatment in the past year.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
David Sutherland. (2026, February 13). Panic Disorder Statistics. Gitnux. https://gitnux.org/panic-disorder-statistics
MLA
David Sutherland. "Panic Disorder Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/panic-disorder-statistics.
Chicago
David Sutherland. 2026. "Panic Disorder Statistics." Gitnux. https://gitnux.org/panic-disorder-statistics.
Sources & references
51 datasets cited across this report · attribution is report-level
+30 additional datasets cited (not shown individually)